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Abstract 
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by 
extensive deposition of amyloid plaques in the brain. These plaques contain an amyloid 
fibril core that is formed through self-aggregation of the P-amyloid peptide (AP), a 
proteolytic product of amyloid precursor protein (APP). AP aggregation is currently 
thought to play a causative role in the development of AD, and thus is an attractive target 
for potential therapeutics. A library of pharmaceutically active compounds (LOP AC) was 
screened for potential inhibitors of AP aggregation using a 96 -well microplate assay. No 
inhibitors were found in the library, but, surprisingly, several compounds exhibited a 
stimulatory effect on AP deposition. Two of the most potent·stimulatory compounds from 
the library (NPC 15437 and calmidazolium chloride) were chosen for more detailed 
studies, with the hope that they might offer some insight into mechanistic and structural 
aspects of AP aggregation, as well as providing possible ideas for drug development. 
NPC 15437 was found to stimulate the nucleation phase of AP aggregation in a 
concentration dependent manner through an interaction with monomeric AP peptide. 
Calmidazolium chloride at a concentration of 100 µM was observed to stimulate the 
formation of an aggregated state of AP that is clearly distinct from mature amyloid 
fibrils. Based on these findings the compounds described here (a) could possibly offer 
insight into the mechanism by which amyloid is formed, as well as the chemical 
structures that are important to amyloid formation, (b) could be used to test the amyloid 
hypothesis in mouse models of AD, and (c) may be of some importance in the 
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I. Background 
Amyloidosis is the term for a series of diseases involving soluble proteins 
aggregated into highly ordered structures termed amyloid fibrils [Sipe, 1 9 9 2  # 1]. Rudolf 
Virchow first applied the term "amyloid" - meaning "starchlike" - to these diseases in 
1853 based on the staining properties of extracellular deposits in human tissue [Selkoe, 
1 9 9 1 # 2]. However, it is now known that amyloid deposits are actually composed of 
proteins, and that they have several common features. They have a high content of P­
pleated sheet secondary structure, as well as a high affinity for the histochemical stain 
Congo red and the fluorescent dye thioflavin T (ThT) [Sipe, 1 9 9 2  # 1]. They are also 
insoluble under physiologic conditions, and are resistant to proteolytic digestion [Sipe, 
1 9 9 2  # 1]. 
Amyloidosis occurs m many human diseases, including type II diabetes, 
Creutzfeldt-Jakob Disease, rheumatoid arthritis, Huntington's Disease (HD), and 
Alzheimer's Disease (AD) [O'Brien, 2000 #3]. The peptide associated with the amyloid 
deposits in AD is the amyloid P-protein (AP) [Selkoe, 1 9 9 1 # 2]. AP exists in many 
forms, ranging from 39 to 43 amino acids in length [Gandy, 1 9 9 2  #4]. It is a product of 
the cleavage of the larger membrane bound amyloid precursor protein (APP) [Selkoe, 
1 98 9  #5 ]. The precise physiological function of APP is unknown, although there is a 
consensus sequence present at the carboxy terminus that is known to mediate endocytosis 
of cell surface proteins [O'Brien, 2000 #3]. It is possible that APP function is related to 
neuronal repair and regeneration [O'Brien, 2000 #3]. 
One hypothesis that has gained popularity is that AP deposition in plaques in 
brain tissue is the causative factor in AD, and that all other pathological symptoms 
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(neurofibrillary tangles, cell loss, vascular damage, and dementia) follow as a result of 
this initial deposition [Hardy, 2002 #6]. Most of the strong evidence in favor of this 
hypothesis is genetic. Early onset forms of AD have been observed to cosegregate with 
mutations in APP [Hardy, 2002 #6]. Most of these mutations have been found to map at 
or near cleavage sites in the primary sequence of APP that are targeted by the proteases 
P- and y- secretase, and therefore generate AP by favoring proteolytic processing of APP 
[Hardy, 2002 #6]. Other familial AD causing mutations that are internal to the AP 
sequence have been linked to changes in aggregation kinetics [Hardy, 2002 #6]. In 
addition, the gene encoding APP has been localized to chromosome 21, and individuals 
with trisomy 21 (Down's Syndrome) inevitably exhibit the neuropathology of AD 
[Masters, 1985 #7]). It is assumed that the third copy of chromosome 21 leads to higher 
levels of AP [Masters, 1985 #7]. Finally, the other known autosomal dominant gene 
mutations that cause early onset AD, the presenilin mutations, have been shown to 
increase the production of AP(l-42) [Hardy, 2002 #6]. The presenilin genes (PS 1 and 
PS2) may alter AP� metabolism by a direct effect on y-secretase [Hardy, 2002 #6]. All of 
these observations are consistent with the theory that AP aggregation plays a causative 
role in AD. 
However, there are some concerns with the amyloid hypothesis. For example, the 
number of amyloid deposits in AD brains does not always correlate with the amount of 
cognitive impairment, while deposition of tau protein in neurofibrillary tangles does ·seem 
to correlate with it [Hardy, 2002 #6]. However, recent findings have suggested that tau 
alterations occur after alterations in APP processing, and also that AP toxicity is tau 
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dependent [Hardy, 200 2 #6]. These observations have led to a theory that smaller 
aggregated forms of AP may in fact be the true disease causing agents [Hardy, 200 2 #6]. 
Thus, it seems reasonable that drug design strategies that target either AP production or 
AP aggregation are viable therapeutic approaches [Esler, 1 9 9 7  #8]. 
To be able to target AP aggregation as a therapeutic approach, it is necessary to 
understand the stages and kinetics of AP fibrillization. The pathway of aggregation of AP 
from peptide to amyloid fibril appears to involve quaternary structural intermediates 
[Kelly, 1 9 98 # 9]. Circular dichroism (CD) has shown that AP fibrils are rich in P-sheet 
secondary structure [Harper, 1 9 9 7  # 10] of a specific type called a "cross-P" conformation 
[Serpell, 2000 # 1 1]. Fibrils also show a high amount of protection against hydrogen­
deuterium exchange of the amide protons along the peptide backbone, which has been 
attributed to extensive hydrogen bonding in the P-sheet core of the fibrils [Kheterpal, 
2000 # 1 2]. 
Analytical ultracentrifugation, electron microscopy, atomic force microscopy, and 
light scattering have all shown that AP( 1 -40 ) at concentrations well above the critical 
concentration (Cr) (see below) exists as both high weight fibrillar oligomers, and also 
sl ightly lower weight oligomers [Harper, 1997 #10 ]. The presence of the smaller 
oligomeric form of AP(l-40 ) suggests that the fibril assembly pathway of AP(l-40 ) 
involves discrete intermediates [Harper, 1 9 9 7 # 10 ]. These intermediates have been 
visualized by electron microscopy [Nybo, 1 9 9 9  # 14]. The earliest observed intermediates 
are globular aggregates about 4 -5 nm in diameter [Nybo, 1 9 9 9  # 14]. These intermediates 
then associate to form short protofilaments ( 10 -20 nm in diameter), which in tum form 
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protofibrils, and subsequently amyloid fibrils through lateral association [Nybo, 1999 
#14]. 
Protofibrillar structures have been observed in the polymerization of both AP( 1-
40) and AP(l-42), suggesting that they are a common intermediate in all AP 
fibrillogenesis [Walsh, 1997 # 15]. Proto fibrils have also been shown to be less resistant 
to hydrogen-deuterium exchange (I. Kheterpal and H. Lashuel, unpublished) than fibrils 
[Kheterpal, 2000 #12], suggesting that early intermediates are not as rich in P-sheet 
structure as fully formed fibrils. It has also been shown that formation of an oligomeric, 
a-helix rich intermediate is common to fibril formation in 18 forms of AP peptide 
[K.irkitadze, 2001 # 16]. It is not clear which intermediate on the fibril formation pathway, 
if any, this a-helical structure represents and its significance in fibrillogenesis remains a 
matter of debate [Kirkitadze, 2001 #16]. It should be noted that all of the observed 
intermediates ( early globular aggregates, protofilaments, and protofibrils) have only been 
seen in vitro. Even so, there is still a possibility that these non-amyloid oligomeric 
intermediates may be the toxic species in AP amyloidosis [Walsh, 1997 # 15]. If so, 
protofibrils would be an attractive target for potential therapeutic agents. 
The presence of a protofibrillar intermediate has been interpreted as being 
consistent with the theory that AP aggregation follows a nucleation dependent pathway 
[Harper, 1997 # 1 0]. Several features characterize nucleation dependent polymerization. 
First, there is no aggregation at peptide concentrations below the critical concentration 
(Cr) [Harper, 1997 # 1 0]. The critical concentration is defined as the concentration of 
peptide at which the rates of fibril formation and fibril dissolution are equal [Harper, 
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1 9 97 #10]. Second, at peptide concentrations that are slightly higher than Cr, there is a lag 
time before aggregation begins [Harper, 1 9 97 #10]. Lag time is defined as the time before 
amyloid formation occurs during which the peptide remains soluble [Harper, 1 9 97 # 1 O]. 
Finally, during the lag time, addition of a small amount of fibril seed results in immediate 
aggregation. Nucleation dependent aggregation is thermodynamically similar to micelle 
formation with respect to the critical concentration, but kinetically is much slower, 
possibly because the process is more complex, and there is a much greater entropic 
barrier to fibril organization [Harper, 1 9 97 #1 O]. 
There are thus three main steps involved in nucleation dependent pathways (see 
Scheme 1 ). The first step, also known as the "nucleation" step, involves conversion of the 
monomer peptide to a thermodynamically unstable "nucleus" that is presumed to be 
oligomeric [Harper, 1 9 97 #10]. During this step, molecules collide to form transitory, 
highly unstable complexes [Harper, 1 9 97 #10]. The nucleus is the least stable oligomer 
on the assembly pathway. As more monomer is incorporated in elongation steps, that 
oligomer becomes more stable. Once the oligomeric nucleus contains more than the 
critical number of molecules, its continued growth leads to the formation of more and 
more stable aggregates, featuring less and less tendency to dissociate to monomer 
[Harper, 1 9 97 # 1 O]. After the formation of this "critical nucleus" comes the "elongation" 
• • 
• • • 
• • 
Aj3 monomer 
.. t.• 4·---___,.. 
Globular and/or 
annular aggregates 
Scheme 1 Amyloid fibril formation 
Proto fibrils Nucleus(?) 
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step of the pathway [Harper, 1997 #1 O]. During this step, where addition of further 
monomers is thermodynamically favorable (see above), rapid extension of the aggregates 
occurs [Harper, 1997 #10] according to pseudo first order kinetics (first order in both 
monomer and fibril growing ends, with the latter unchanging over the course of the 
reaction). The final phase of the pathway occurs when the peptide monomer is depleted 
to the point where fibril growth and dissolution are in a dynamic equilibrium [Harper, 
1997 #10]. 
Fibril growth is more complex in vivo, however. For instance, factors such as 
chemical damage and binding of other proteins can render fibrils stable to dissociation 
[Harper, 1997 #10]. For example, apolipoprotein E2 (apoE2) is an endogenous protein 
that has been shown to inhibit amyloid fibril formation [Harper, 1997 #10]. Also, cellular 
concentrations of AP are much lower in vivo than those typically used in vitro, which 
makes it unclear how nucleation can occur in vivo [Harper, 1997 #10]. It may be possible 
that nucleation occurs in cellular organelles with a supersaturated AP concentration, and 
fibrils formed in this way can then be released from the cellular compartment and act as 
seeds for additional fibril formation [Harper, 1997 #1 O]. 
A number of assays have been developed for following amyloid fibril growth in 
vitro [Levine, 1999 # 17]. One assay that can be used to monitor spontaneous aggregation 
of AP in solution monitors the change in fluorescence that accompanies ThT binding to 
fibrillar aggregates [Levine, 1999 # 17]. This assay can be used to monitor either 
unseeded AP aggregation (nucleation and elongation phases of aggregation), or seeded 
AP aggregation (elongation phase of aggregation) [Naiki, 1999 #18]. Another assay 
[Esler, 1997 #8] that has been developed uses a 96 well microplate to monitor deposition 
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of AP monomer onto an immobilized fibrillar template. The microplate assay is similar to 
the ThT assay of seeded AP aggregation, except that the fibril seeds are immobilized on a 
plastic swface. One benefit of the microplate assay is that it can be used with peptide 
concentrations on the order of 10 nM, as opposed to the ThT assay, which uses peptide 
concentrations of 30 µM. Also, the microplate assay offers a much higher throughput 
than the Th T assay. 
High throughput assays such as the microplate assay described above [Esler, 1997 
#8] lend themselves well to drug screening. In the drug screening process, a large number 
of pharmaceutically active chemicals can be tested in a biological system to determine 
which, if any, exhibit an effect on that system [Esler, 1997 #8]. For example, high 
throughput screening identified a small molecule that activates caspase-3 in cancer cells, 
and this discovery in turn revealed information about the regulatory pathways in tumor 
suppressor activity and apoptosis in these cancer cells [Jiang, 2003 #20]. High throughput 
screening has also been used to look for potential therapeutics in Alzheimer's disease 
[Reixach #21, Esler #8] by looking for compounds that affect AP fibril formation. 
Inhibition of AP aggregation is a very appealing target for drug design [Lansbury, 
1997 #22]. Studies have shown that AP immunizations in murine models of Alzheimer's 
disease reduce both the level of fibrillar AP deposition in the brain and the level of 
cognitive decline [Janus, 2000 #23]. These findings suggest that there is a link between 
AP aggregation/deposition in the brain and cognitive decline in Alzheimer's disease. 
Therefore, screening libraries of compounds for inhibitors of AP aggregation and/or 
deposition could lead to the discovery of novel drug candidates for treating Alzheimer's. 
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Interpretation of the results of such screens is complicated, however, due to the 
uncertainty about what the toxic aggregate is (i.e., the possibility that an intermediate on 
the fibril assembly pathway may be the toxic species, while mature amyloid fibrils may 
actually be protective) [Hardy, 200 2 #6]. 
The high throughput microplate assay described previously [Esler, 1 9 97 #8] can 
be used to screen a large number of compounds for potential inhibitors of AP deposition. 
A similar assay has been developed to screen for inhibitors of aggregation of the amyloid 
peptide polyglutamine (polyQ) [Berthelier, 200 1 # 24]. The biggest advantage of this 
assay over the assay described in [Esler, 1 9 97 #8] is that it avoids the use of radioactivity. 
This assay has been adapted to identification of inhibitors of AP aggregation (R. Wetzel, 
unpublished). 
Using this assay, we set out to identify inhibitors from a collection of compounds 
that had been prepared for use in drug screening. The Library of Pharmaceutically Active 
Compounds (LOPAC) from Sigma was screened for potential inhibitors. The LOPAC 
library contains 640 pharmaceutically active compounds dissolved in dimethyl sulfoxide 
(DMSO). The choice of DMSO in the library is because of its "universal solvent" 
properties. If the solubility limit of each compound in the library had to be determined 
individually, the overall assay process would bog down, despite the existence of a high 
throughput assay. In fact, not all compounds are soluble in 100% DMSO, and some 
compounds have limited solubility when diluted from DMSO into an aqueous buffer. 
However, the loss of some potentially useful compounds due to solubility issues is 
outweighed by the gains in sheer numbers that accompany high throughput analysis. 
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When the LOPAC library was screened for potential inhibitors of polyQ 
aggregation, several were found (V. Berthelier, T. Richey, unpublished). The use of the 
AP version of this microplate assay to screen the LOPAC library is described here. In 
fact, no inhibitors of AP were identified. Instead, several compounds were found that 
apparently stimulate deposition of AP in vitro. These compounds, whose discovery and 
preliminary characterization are also described here, may offer insight into the 
mechanism of AP aggregation, and possibly help elucidate the three dimensional 
structure of AP aggregates. Compounds in these classes may also prove to be important 
therapeutics, if they are stimulating the formation of a non-toxic aggregated state of AP. 
9 
II. Materials and Methods 
Peptides. AP ( 1 -40) peptide was obtained by custom solid phase synthesis from the Keck 
Biotechnology Center at Yale University. The biotinylated form of the peptide was 
prepared ( R. Wetzel, unpublished) by alkylation of the sulthydryl group of Cys· 1-AP( l-
40) with PEO-iodoacetyl biotin ( Pierce, Rockford, IL). 
Disaggregation and solubilization of AJ} (1-40) peptides. Disaggregation and 
solubilization of AP (1-40 ) peptide was performed as described previously [Jao, 199 7 
#25]. Thus, AJ} (1-40) peptide was dissolved in trifluoroacetic acid ( TFA) ( Pierce, 
Rockford, IL) at a concentration of 1 mg/ml and sonicated for 15 minutes to remove any 
remaining aggregates. The TF A was then evaporated under a stream of argon in a fume 
hood. The peptide residue was then solubilized in 1 ,1 , l ,3 ,3 ,3- hexafluoro-2- propanol 
( HFIP) ( Sigma, St. Louis, MO) at a concentration of 1 mg/ml and incubated for one hour 
at 3 7°C. At this point, the HFIP was evaporated under a stream of argon in a fume hood, 
and the peptide residue solubilized once more in HFIP at 1 mg/ml, and the solution 
aliquoted into test tubes with 0.5 mg of AP (1 -40) per test tube. The solvent in each test 
tube was evaporated under argon, and the peptide residue was placed under vacuum for 
one hour to remove any remaining TF A and HFIP. The peptide residue was then 
dissolved at a concentration of 0.5 mg/ml in 1 X PBS at a pH of 7 .4 and this solution was 
centrifuged at 100 ,000 g for 1 7  hours to remove any aggregated peptide. The supernatant 
was collected, and the exact concentration of AP (1 -40) determined by reverse phase high 
performance liquid chromatography ( RP-HPLC) ( Hewlett- Packard, Palo Alto, CA) using 
a Zorbax SB- C3 column on an Agilent system 1100. Thus, 10 µL of solubilized peptide, 
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diluted 10 times in 0.1 % TFA, was injected onto the column and analyzed with a 0-50% 
(v/v) acetonitrile gradient in 0.05% TFA applied at a rate of 2% per minute. The· peak 
area obtained at 215 nm was compared to a standard curve previously established with 
AJ3 (1-40) whose concentration had been determined independently by amino acid 
composition analysis. All peptides were snap-frozen and stored at -80°C prior to use. 
Preparation of AP (1-40) fibrils. AJ3 (1-40) peptide solubilized as described above was 
adjusted to a concentration of 28. 9 µM (0.125 mg/ml) in buffer containing PBS IX  and 
NaN3 0.05% and incubated at 37°C. After 14 days, the fibrils were collected by 
centrifuging at 20,000g for 25 minutes and resuspended in extension buffer (PBS IX, 
0. 01 % tween 20, and 0.05% NaN3). The quality of the fibrils was checked by thioflavin-T 
(ThT) fluorescence and electron microscopy (EM). An aliquot of the fibrils was dissolved 
in TF A, and the exact concentration of the fibrils was determined using RP-HPLC to 
determine the amount of AP in the aliquot as described above. The fibrils were then 
sonicated for 5 minutes, snap-frozen in liquid nitrogen, and stored at -80°C. 
Microplate preparation. AP (1-40) fibrils prepared as described above (or other AJ3 
aggregates, as described below) were fixed to activated ELISA 96-well microtiter plates 
(EIAIRIA Plates, Costar, Atlanta, GA) by passive adsorption. The microplates were 
incubated uncovered at 37°C for 17 hours with 100 µL of AP (1-40) fibrils diluted to a 
concentration of 1 µg/ml in 72 wells, which gave 100 ng of AJ3 ( 1-40) fibrils per well, 
and 100 µL of extension buffer in the remaining 24 wells as a negative control to 
measure any background signal. After the 1 7 hour incubation, the wells were washed 
three times with extension buffer, incubated for one hour at 37°C with 100 µL of 0. 3% 
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(w/v) gelatin in extension buffer to block any remaining surfaces in the wells not bound 
with fibrils, and again washed three times with extension buffer. The microplates were 
used immediately following this treatment. 
Kinetics assay. Prior to the assay, 90 µL of extension buffer was added to each well. For 
kinetic measurements with compounds, 80 µL of extension buffer was added to each 
well, followed by 10 µL of compound dissolved in DMSO (at an appropriate 
concentration) prior to starting the extension assay. For each replicate of each time point, 
10 µL of 100 nM biotinyl-AP (1-40) was added to the wells, after which the plate was 
covered with an adhesive overlay and incubated at 37°C. Each time point was analyzed in 
triplicate (three wells) in reverse temporal order. Thus, the wells which have biotinyl-AP 
(1-40) added at the start of the assay will give the longest time point of the data. At each 
subsequent time point, the plate was removed from the incubator and uncovered, 10 µL 
of 100 nM biotinyl-AP (1-40) was added to the next set of wells, and the plate was re­
covered and returned to the incubator. This process was repeated until all of the intended 
time points had been set up. 
Microplate signal generation. After the incubation for the final time point, the extension 
reactions were stopped simultaneously by washing each well three times with extension 
buffer using the stream from a wash bottle. To generate the signal for the microplate, 
each well was then incubated for one hour at room temperature with 100 µL of a 100 
ng/mL europium-streptavidin (EG&G Wallac, Gaithersburg, MD) solution in extension 
buffer containing 0.5% bovine serum albumin (S igma) (BSA). After this incubation, the 
wells were washed three times with extension buffer, and the europium was released 
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from the streptavidin by adding 1 00 µL of an enhancement solution (EG&G Wallac) 
[Hemmila, 1 984 #26] . After 5 minutes, the europium was measured by time-resolved 
fluorometry [Dimandis, 1 988 #27] in a Victor 2 (EG&G Wallac) microtiter plate reader 
using the programmed parameters for counting europium. Europium counts obtained by 
this method were converted to fmoles of europium using a standard curve obtained with a 
standard europium solution from EG&G Wallac (not shown). Fmoles of europium were 
then converted to fmoles of biotinyl-AP ( 1 -40) using the manufacturer determined ratio 
of 7 Eu3+ ions per streptavidin molecule. 
Primary screen of LOPAC library. The LOPAC library (Sigma, St. Louis, MO) is 
provided in eight 96 well plates. Each plate has 80 wells containing pharmaceutically 
active compounds dissolved at concentrations of 1 mM in 1 00% dimethyl sulfoxide 
(DMSO), and 1 6  wells containing pure DMSO as controls. For the screening of each 
plate in the library by the extension assay, three microplates were coated with AP ( 1 -40) 
fibrils, as described above, for triplicate measurements. 80 µL of extension buffer was 
added to all of the wells in each plate, followed by 1 0  µL of the LOP AC library solutions 
in the wells corresponding to their position in the LOPAC library plates, giving a final 
concentration of 1 00 µM compound in each well. Next, 1 0  µL of 1 00 nM biotinyl-AP 
was added to each well. The microplates were then incubated at 3 7°C for thirty minutes. 
The extension reaction was then stopped by washing each well three times with extension 
buffer, and the signal for each plate was generated as described above. 
Dose response studies. Microplates were coated with AP (1 -40) fibrils as described 
above, and 90 µL of compounds that showed a stimulatory effect on AP ( 1 -40) extension 
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in the primary screen of the LOPAC library were added to the wells at concentrations 
ranging from O to 1 00 µM in extension buffer containing 1 0% DMSO. Each 
concentration of compound was added to three wells for triplicate measurements. Next, 
1 0  µL of 1 00 nM biotinyl-AP was added to each well. The microplates were then 
incubated at 3 7°C for thirty minutes. The extension reaction was then stopped by 
washing each well three times with extension buffer, and the signal for each plate was 
generated as described above. 
Washout assay. Microplates were coated with AP ( 1 -40) fibrils as described above, and 
90 µL of compounds that showed a stimulatory effect on AP ( 1 -40) extension in the 
primary screen of the LO PAC library were added to the wells at a concentration of 1 00 
µM in extension buffer containing 1 0% DMSO. The microplate was incubated at 25°C 
for 60 minutes. The compounds were removed from the microplate by washing each 
well three times with extension buffer. In one set of three wells, the kinetic assay was 
conducted as described above. 1 00 µL of extension buffer was added to another set of 
three wells, incubated at 25°C for 1 20 minutes, and washed three times with extension 
buffer. The kinetic assay was then conducted as described above. 
Solution phase aggregation assays. The most potent compounds from the LOP AC 
library as determined by the dose response studies were purchased from Sigma for more 
detailed study (see Results section). To determine the effect of these compounds on AP 
( 1 -40) aggregation kinetics in solution, AP ( 1 -40) rigorously disaggregated as described 
above was incubated at 28.9 µM in PBSA ( IX PBS, 0.05% NaN3) buffer with compound 
concentrations ranging from O to 1 00 µM. As a control, AP ( 1 -40) was also incubated at 
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28 .9 µM in PBSA at 37°C in the presence of fibril seeds at 0 .05% the weight of AP ( 1 -
40 ) monomer in the reaction. The aggregation kinetics were followed by ThT 
fluorescence measurements [Levine, 1 9 9 9  # 17], by RP-HPLC analysis [Naiki, 1 9 9 9  # 18], 
and by 90 ° light scattering at 450 nm [Wood, 1 9 9 6  # 1 9] as described previously. Thus, a 
ThT fluorescence signal was generated by diluting a 10 µL aliquot of each reaction 
solution to a final volume of 400 µL in PBSA containing 15 µM ThT, and measuring 
fluorescence of the sample in a fluorometer with the excitation wavelength set to 44 2 nm 
and the emission wavelength set to 48 2 nm. The fluorescence data for each time point 
was collected over one minute, and then averaged. Each time point was analyzed in 
triplicate. For RP-HPLC analysis, a 30 µL aliquot of each reaction was diluted 5 -fold into 
ice-cold PBSA to stop the aggregation reaction, put on ice, and centrifuged at 100 ,000 g 
for 25 minutes at 4 °C. The upper 100 µL of the supernatant was collected, and TFA 
added to a concentration of 1 % (v/v). The sample was then analyzed for the amount of 
soluble AP ( 1 -40 ) by RP-HPLC as described above. 90 ° light scattering measurements 
for each sample were obtained by diluting a 10 µL aliquot of each reaction solution to a 
final volume of 400 µL in PBSA and measuring the light scattering with excitation and 
emission wavelengths both set to 450 nm and slit widths set to 1 0  nm. To determine the 
effect of the compounds on the structure of the AP ( 1 -40 ) aggregation products, aliquots 
of each reaction mixture were collected after 2 days and after 14 days and analyzed by 
electron microscopy. All electron micrographs were generated by the Life Sciences 
Electron Microscopy Facility at the University of Tennessee, Knoxville. 
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Collection and storage of aggregates. Aggregates were collected by centrifuging 
aliquots of various time points for each solution phase reaction at 20,000g for 25 minutes 
at 4°C, removing the supernatant, and resuspending the pellet in PBSA. This process was 
repeated three times to remove any remaining unbound compound from the reaction 
mixture. The exact concentration of the Af3 ( 1-40) aggregates was determined by 
centrifuging an aliquot of the resuspended pellet, and dissolving in TF A as described 
above, and measuring the concentration of Af3 (1-40) by RP-HPLC as described above. 
The resuspended pellet was then snap-frozen, and stored at -80°C until used. 
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III. Results 
Since AP aggregation is implicated in the disease mechanism of Alzheimer's 
disease, compounds that influence AP aggregation may be potential therapeutics. A 
microtiter plate assay for AP extension has been developed (R. Wetzel, unpublished) 
which provides a high throughput way of screening large numbers of potential inhibitors. 
Figure 1 shows the typical kinetic time course observed in this assay1 . The time course is 
characterized by an initial fast phase of extension, and a second slow phase of extension. 
We decided to conduct the primary screen of the Library of Pharmaceutically Active 
Compounds (LOP AC) by stopping the extension reaction after 30 minutes, which 
corresponds approximately to the midpoint of the fast phase. The LOP AC library 
contains 640 pharmaceutically active compounds dissolved in dimethyl sulfoxide 
(DMSO) at a concentration of 100 µM. Thus, dilution of the compound solutions into 
aqueous buffer will produce a mixed aqueous solvent containing a small amount of 
DMSO which could potentially influence the assay results. DMSO has been shown, 
h�wever, to have no effect on the analogous kinetic determination of polyglutamine 
elongation as observed in the microtiter plate assay [Berthelier, 2001 # 24 ]. Figure 2 
shows that similarly there is no significant effect of DMSO up to a 10% concentration on 
AP extension in the microtiter plate assay after 30 minutes. 
Figure 3 shows the results of the primary screen of the LOP AC library, with each 
bar on the graph representing one compound. The percent inhibition of each compound is 
calculated by the equation 
(1 ) I =  [(Cn - Ci)/Cn]* l00 
1 All figures are located in the Appendix. 
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where 
I = Percent inhibition 
C0 = Amount ofbiotinyl-AP deposited in absence of compound 
Ci = Amount of biotinyl-AP deposited in presence of compound 
Surprisingly, none of the compounds in the LOPAC library showed any significant 
inhibition (greater than three standard deviations from the average) of AP deposition in 
the microplate assay. However, seven compounds actually stimulated (showed a negative 
percent inhibition of) deposition of Ap. The compounds - amiloride HCl, phenamil 
methane sulfonate, naftopidil dihydrochloride, NPC 1 543 7 dihydrochloride, 
calmidazolium chloride (R2457 1 ), 5-(nonoxyl)-tryptamine hydrogen oxalate, and L-a­
methyl DOPA - have a wide variety of structures and biochemical properties (see 
Discussion section). The structures of these seven compounds are shown in Figure 4, 
along with the percent stimulation observed in our experiments. Even though the only 
hits observed in the initial screen exhibited stimulatory effects, they could still prove 
useful in gaining information about the biochemical process of AP aggregation (see 
Discussion). 
Interestingly, several catechol-containing compounds, similar in structure to L-a­
methyl DOPA, were initially identified as modulators of a-synuclein fibrilization, and 
were also identified as inhibitors of polyglutamine aggregation (V. Berthelier, 
unpublished). In both cases, it was subsequently determined that the species acting as the 
inhibitor was actually the oxidized quinone form of the compound [Conway, 2001 #28] . 
Since the LOPAC library had been stored prior to the screen, it may be possible that a 
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similar oxidized form of L-a.-methyl DOPA is the active species in AJ3 aggregation 
stimulation as well (see Discussion section). However, no experiments were performed to 
test this hypothesis. One reason for this is that the stimulation exhibited by L-a.-methyl 
DOPA was marginal, compared to some of the other compounds (see below). 
As part of the overall screening process, it is important to examine the 
concentration dependence of the hits. Figure 5 shows the results of such dose response 
studies (see Materials and Methods) for each of the seven compounds. The 
concentrations of the compounds in the dose response studies ranged from 0 .05 to 100 
µM. Interestingly, only calmidazolium chloride showed a saturation effect for stimulation 
in this concentration range (Figure 5 C). Calmidazolium chloride shows maximal 
stimulation at a concentration of 50  µM, while the stimulation of the other six compounds 
still appear to be increasing even at concentrations of 100 µM. 
Compound potencies are described as ECso values. The ECso value of a 
compound is defined as the compound concentration at which the measured effect is half­
maximal. The transition region of each dose response curve is identified as the region in 
which the percent stimulation begins to increase from values corresponding to no effect. 
Fitting the data points in the transition zone to a straight line through a linear regression 
gives an equation that can be used to calculate an ECso value for each compound. 
However, because calmidazolium was the only one of the seven compounds that showed 
a saturation effect (and hence a plateau such that a maximal effect could clearly be seen), 
it is the only compound for which a true ECso could be calculated. That is to say, since 
the effects of the other six compounds at concentrations higher than 100 µM were never 
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determined, it may be possible that the calculated EC50 values are underestimates of the 
true EC50 values. Figure 5 shows the straight line fits for the transition region of each 
dose response curve, while the apparent EC50 values for each compound are given in 
Figure 4. Based on the calculated EC5o values of the seven compounds, calmidazolium 
chloride (EC50 = 2 1.4 µM), NPC 15437 (ECso � 27.2 µM), phenamil methane sulfonate 
(EC50 � 35. 5 µM), and 5-(nonyloxy)-tryptamine hydrogen oxalate (ECso � 30 .3 µM) are 
the most potent stimulators of A� deposition. L-cx-methyl DOPA (ECso � 34.2 µM) is the 
least potent stimulator. 
Three of the four most potent compounds - calmidazolium chloride, NPC 1543 7, 
and phenamil methane sulfonate - are readily available from Sigma, and were therefore 
chosen for more detailed study. Amiloride HCl was also chosen for additional study 
because structurally (a) it very closely resembles phenamil methane sulfonate (Figures 
4 A  and 4 B), and (b) both compounds have structural elements suggestive of peptide 
bonds, which play a significant role in the formation of the �-sheet structure of fibrils. 
Once compounds have been identified in the initial screening process, it is important to 
obtain fresh compounds for further testing for two main reasons. First, testing fresh 
compounds makes sure that no mix-ups occurred in the original screening, and second, it 
can identify problems with long term storage of the compounds in DMSO ( e.g. oxidation 
of dihydroquinones to quinones mentioned above). All four compounds to be retested 
were purchased from Sigma. 
First, we set out to confirm the behavior of these apparent stimulators by 
conducting full kinetic analyses of each compound (rather than one time point) in the 
mi crop late assay. Figure 6 A  shows the kinetic time course of A� deposition in the 
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microplate assay in the presence and absence of calmidazolium chloride. The results 
show that calmidazolium chloride significantly increases the rate of deposition, as well as 
the amount of Af3 deposited. Figure 6B shows the kinetic time course of Af3 deposition in 
the microplate assay in the presence and absence of NPC 1543 7. These results show that 
NPC 1543 7 also stimulates both the rate and amplitude of the kinetic curve, although not 
as potently as calmidazolium. 
Figures 6C and 6D show similar kinetic time course data for amiloride HCl and 
phenamil methane sulfonate. These two figures show that freshly dissolved amiloride 
HCl and phenamil methane sulfonate appear to have an inhibitory effect on the kinetics 
of Af3 deposition in the microplate assay. The contradiction between this result 
( inhibition) and the initial screening result ( stimulation) for these two compounds may be 
due to the fact that they were not stored in DMSO for any length of time prior to the 
assay, in contrast to the compounds in the LOPAC library that had been stored for several 
months in DMSO prior to the primary screen . The storage of the compounds for an 
extended period of time may have led to a degradation product of amiloride and 
phenamil, which are highly similar structurally, and the degradation product may be the 
species responsible for the stimulation of Af3 deposition in the primary screen . In any 
case, the apparent inhibition by these two compounds was not great enough to warrant 
further investigations, and they were not studied further. 
The solid phase microtiter format allows an assay modification that can be used to 
probe which molecular species is the target of the compounds' activity . This 
modification, termed the "washout assay" ( see Materials and Methods) can be used to test 
whether the stimulating effects of calmidazolium chloride and NPC 1543 7 in the 
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microplate assay were due to interactions with the preformed fibrillar AP on the plate or 
with the solution-phase biotinyl-AP. The washout assay has been used successfully in 
studying inhibitors of polyglutamine aggregation to show that the inhibitors act through 
interactions with the polyglutamine aggregates rather than the monomer (V. Berthelier, 
unpublished). The washout assay results for NPC 15437 are shown in Figure 7. These 
results show that washing the wells that had been incubated with NPC 15437 
immediately prior to starting the extension assay gives a kinetic time course that is 
virtually indistinguishable from the kinetic time course of AP deposition in the absence 
of the compound. However, in the continual presence ofNPC 15437 an amplified kinetic 
curve is observed. The rates and amplitudes of both phases of this kinetic curve are 
significantly greater than those observed in the absence of NPC 15437. Also, absolutely 
no deposition of AP is observed when biotinyl-AP is incubated with NPC 15437 in the 
absence of a preformed fibrillar template (Figure 7B). These results suggest that NPC 
15437 is stimulating deposition of AP through some sort of interaction with the AP 
monomer, and that if there is any non-covalent binding between NPC 1543 7 and fibrillar 
AP aggregates then that binding is very weak. 
Figure 8 shows the results of the washout assay for calmidazolium chloride. The 
results of the washout assay indicate that calmidazolium chloride stimulates AP 
deposition even if it is removed from the solution phase prior to the extension assay. 
However, the stimulatory effect is decreased when the wells are incubated in extension 
buffer for two hours after the removal of the compound before starting the assay. 
Together these results suggest that (a) calmidazolium acts by binding to the fibrillar AP 
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aggregates and (b) that this binding is not extremely tight, since some compound can 
dissociate after incubation of the plate in extension buffer for two hours. 
As a control in the washout assay, some microtiter plate wells without 
immobilized fibril seeds were incubated for 4 hours at 3 7°C with a solution of biotinyl­
AP plus calmidazolium. Surprisingly, strong two phase kinetics are obtained even in the 
absence of a preformed fibrillar template, as shown in Figure 9 .  There are a number of 
possible explanations for this unexpected effect. For example, it is possible that 
calmidazolium interacts with the gelatin blocking agent in the microplate wells, 
converting the gelatin to a fibril-like seed capable of being elongated with Ap. However, 
Figure 10 shows that even without a preformed fibrillar template, AP deposition is 
stimulated in the presence of calmidazolium regardless of whether the microplate wells 
are blocked with 0 .3% gelatin buffer or with 0 .5%BSA buffer. However, calmidazolium 
does not stimulate AP deposition as greatly in microplate wells blocked with 0 .5% BSA, 
and it does not show strong two phase kinetics. The fact that calmidazolium still 
stimulates AP deposition in microplate wells blocked with 0 .5% BSA suggests that 
calmidazolium does not act through a direct effect on the blocking agent. Another 
possibility is that calmidazolium is acting via an interaction with the monomeric Ap. It 
should be noted, however, that to produce this effect calmidazolium must not only 
stimulate AP aggregation, but it must also stimulate the deposition of the aggregates on 
the plate. In addition, these aggregates must be elongation competent, but it is not clear 
from these experiments whether or not this is the case. To better understand the nature of 
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the effect that calmidazolium has on AP aggregation, it is necessary to use additional 
assays. 
The microplate assay acts as an in vitro model of the elongation phase of AP 
aggregation. Solution phase assays have also been described [Levine, 1999 # 17] that act 
as in vitro models of spontaneous aggregation ( both the nucleation and elongation 
phases) of AP. These solution phase assays are important for several reasons. First, they 
can be used to confirm that the microplate results are accurate. Second, they can reveal 
whether the effect of the compounds on the nucleation phase of aggregation is different 
than the effect on the elongation phase. And finally, they offer a way to further explore 
the mechanism of calmidazolium action on AP . 
These assays depend on the ability to monitor fibril growth either directly - by 
monitoring ThT fluorescence [Levine, 1999 #17] - or indirectly - by monitoring the 
depletion of AP monomer by HPLC [Naiki, 1999 #18 ]. To use the ThT assay, we first 
had to confirm that the test compounds have no effect on fluorescence under assay 
conditions. Figure 11 shows that calmidazolium chloride has no significant effect on ThT 
fluorescence at concentrations ranging from 0 .1 µM to 1 mM in the presence or absence 
of AP fibrils. Similarly, Figure 12 shows that NPC 15437 has no significant effect on 
ThT fluorescence over the same concentration range. Therefore, fibril growth in the 
presence of each compound can be monitored by ThT fluorescence without having to 
correct for high background signals due to direct fluorescence effects of the compounds. 
Figure 13 A shows the kinetic time course of AP aggregation monitored by ThT 
fluorescence in the presence of NPC 15437 at concentrations ranging from O to 100 µM, 
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while Figure 13B shows the kinetic time courses for the same aggregation reactions 
monitored by RP-HPLC. Interestingly, the ThT results show that as the concentration of 
NPC 15437 is increased, the lag time to aggregation is decreased. This suggests that NPC 
15437 is acting by stimulating nucleation of amyloid fibril formation by the AP 
monomer. However, even at NPC 15437 concentrations of 100 µM there is still a lag 
time of approximately 4 days. As the ThT signal increases to a maximum, the level of AP 
left in solution drops to a base level. These results suggest that NPC 15437 does indeed 
stimulate the nucleation stage of AP aggregation. 
It is also interesting that, contrary to previous observations [Wood, 1 9 9 6  # 1 9] 
when measured by RP-HPLC the level of AP monomer decreases well before any ThT 
signal develops, even in the absence of NPC 15437. One possible explanation for this 
result is that the reaction aliquots were centrifuged at 100 ,000 g for 25 minutes to remove 
any aggregated AP (see Materials and Methods) as opposed to 14 ,000 g as described 
previously [Wood, 1 9 9 6  # 1 9]. Thus, it is possible that early intermediates on the pathway 
from AP monomer to fibril are only removed by extremely rigorous centrifugation and 
that the formation of these intermediates, if they are ThT negative, would account for the 
decrease in monomeric Ap. Non-fibrillar aggregates are clearly present at the 2 -day 
point, as shown in Figure 14 . The secondary structure of AP fibrillogenesis intermediates 
is difficult to measure, and there is currently no consensus on the extent to which 
protofibril substructure resembles that of fibrils [Kirkitadze, 200 1 # 1 6]. At the end of the 
lag phase the ThT and RP-HPLC results shown in Figures 13A and 13B seem to agree. 
The correspondence between the results of the ThT and RP-HPLC assays after the lag 
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phase suggests that the bulk of the aggregates formed in the presence of NPC 154 3 7 are 
indeed fibrillar, in direct contrast to the results for calmidazolium ( see below). 
Figures 16, 17, and 18 show EM images of AP aggregates grown for fourteen 
days in the presence of NPC 15437 at concentrations ranging from O to 100 µM. These 
aggregates show structures very similar to those of fibrils grown in the absence of any 
compound ( Figure 15). In fact, the aggregates grown in the presence of 10 µM NPC 
15437 ( Figure 17) appear to be even larger than untreated aggregates ( Figure 14 ). It may 
be possible that NPC 15437 is somehow acting to stabilize the fibrillar state of the AP 
aggregates and enabling them to grow larger than usual. It may also be possible that NPC 
15437 is somehow stabilizing key intermediates in the fibrillization pathway, thereby 
altering their steady state concentrations and in tum changing the observed rate. 
Isothermal titration calorimetry experiments did not indicate a titration between NPC 
15437 and AP up to a molar ratio ( NPC/AP) of 50 ( data not shown). It is also possible 
that this compound is destabilizing off- pathway AP assemblies, effectively increasing the 
concentration of AP monomer or of some other critical on-pathway intermediates. 
Figure 19 shows the kinetic time course of AP aggregation monitored by ThT 
fluorescence in the presence of calmidazolium chloride at concentrations ranging from O 
to 100 µM. Interestingly, after 14 days the ThT signal of fibrils grown in the presence of 
100 µM calmidazolium chloride has an intensity that is approximately 25% of the 
intensity of the ThT signal of fibrils grown in the absence of calmidazolium. 
Furthermore, as the concentration of calmidazolium is lowered, the intensity of the ThT 
signal increases. This suggests that the AP aggregates formed in the presence of 
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calmidazolium are significantly less fibril-like than fibrils grown normally, since ThT 
fluorescence is proportional to the amount of fibrils present [Levine, 1 999 # 1 7] .  
Figure 20  shows .the kinetic time course of  AP aggregation monitored by RP­
HPLC in the presence of calmidazolium chloride at concentrations ranging from 0 to 1 00 
µM. These results show that calmidazolium at a concentration of 1 00 µM completely 
depletes the AP monomer in solution after only one day. However, Figure 1 9  shows that 
at the same time point under these reaction conditions, no appreciable ThT signal can be 
seen. This suggests that calmidazolium is driving AP into an aggregated state that is not 
amyloid. This profile is similar to that implied by the lack of ThT signal observed for 
early AP assembly intermediates in the absence of added compound (see above). 
Figure 2 1  shows the kinetic time course of AP aggregation monitored by 90° light 
scattering at 450 nm. It is interesting that only AP aggregates grown in the presence of 
1 00 µM calmidazolium show any appreciable light scattering signal. The light scattering 
of these aggregates appears after one day, which fits with the data obtained by RP-HPLC. 
It also supports the theory that AP is rapidly aggregating in the presence of 1 00 µM 
calmidazolium. 
To get a more detailed look at the early events due to the effect of calmidazolium, 
the reactions were repeated and hourly time point measurements taken. Figure 22A 
shows the hourly time course of AP aggregation monitored by light scattering at 450 nm, 
while Figure 22B shows the same hourly time course as monitored by RP-HPLC. 
Interestingly, after only two hours the RP-HPLC measurement of the AP monomer 
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remaining in solution decreases from an initial value, while at the same time point, the 
light scattering signal increases from a baseline. 
Based on the RP-HPLC data, AP monomer m the presence of 1 00 µM 
calmidazolium is significantly depleted almost within 1 -2 hours (Figures 22B). This 
depletion of monomer is accompanied by a simultaneous increase in light scattering 
(Figures 2 1  and 22A). Also, after one day at these reaction conditions a precipitate is 
observed. However, this precipitate is not the test compound, since no precipitate is 
formed when calmidazolium is incubated in buffer without AP present (not shown). 
These results indicate that calmidazolium is indeed stimulating aggregation of AP in 
solution. However, there is a significant reduction in the ThT signal of these aggregates 
compared to an equal weight of bona fide fibrils (Figure 1 9). One possibility that could 
reconcile these apparently contradictory observations is that calmidazolium is acting 
somehow to drive the AP monomer into a non-fibrillar aggregated state. The implication 
that calmidazolium stimulates aggregation of AP in a non-fibrillar form is not 
inconsistent with the original microplate result, because the microplate generates a 
positive signal for AP deposition regardless of whether or not the deposited product is 
fibrillar (see Materials and Methods). 
Electron microscope (EM) images of AP aggregates grown for two days and AP 
aggregates grown for fourteen days at calmidazolium chloride concentrations ranging 
from O to 1 00 µM are shown in Figures 23 through 28. Figure 14  shows that after two 
days, aggregates grown in the absence of calmidazolium show globular structures similar 
to those reported by others for AP amyloid assembly (see Background), and very few 
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fibrils. However, Figure 23 shows that after two days, aggregates grown at a 
calmidazolium chloride concentration of 100 µM are very large, and do not appear to be 
fibrillar (although these globular assemblies appear to contain short, filamentous 
substructures). Figure 2 4  shows that after two days, aggregates grown at a calmidazolium 
concentration of 10 µM have a more ordered structure than aggregates grown without 
calmidazolium, but these structures are not as large as those seen in aggregates grown in 
100 µM calmidazolium. Compared to the EM images of the control fibrils (Figure 15 ), 
none of these aggregates appear to be fibrillar, which agrees with the ThT data (Figure 
1 9 ). However, Figure 25 shows that after two days, Af3 aggregates grown in the presence 
of 1 µM calmidazolium appear to be highly fibrillar. This suggests that calmidazolium at 
concentrations below 10 µM enhances Af3 fibril formation, perhaps by stabilizing key 
intermediates in the amyloid assembly pathway. Circular dichroism experiments to 
determine the amount of (3-sheet secondary structure in the non-fibrillar aggregates 
proved unsuccessful, due to the large amount of light scattering associated with them 
( data not shown). 
Figure 15 shows the structure of fibrils grown in the absence of calmidazolium 
chloride after fourteen days. Figure 2 6  shows the structure of aggregates grown in the 
presence of 100 µM calmidazolium after the same amount of time. Interestingly, the large 
aggregated structures present after two days at these reaction conditions are still present, 
but fibrillar aggregates are now also present. At calmidazolium concentrations of 10 and 
1 µM, the aggregated structures all appear to be fibrillar (Figures 27 and 28 ). From the 
EM images, it seems as though 100 µM calmidazolium is indeed driving Af3 into a non-
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fibrillar aggregated state after only one day. However, after fourteen days AP fibrils are 
also present under these conditions, as seen in Figure 26. This could possibly be caused 
by the non-fibrillar AP aggregates rearranging to form fibrils, either by a direct 
transformation within the solid phase, or mediated by a small amount of solution phase 
If the aggregates that form rapidly in the presence of calmidazolium are indeed 
non-fibrillar, then they should exhibit no ability to seed wild type AP fibril 
formation/elongation. We tested the seeding ability of aggregates formed in the presence 
of calmidazolium using the microplate assay. Aggregates grown in the presence of 
calmidazolium at concentrations of 0 ,  10 , and 100 µM were collected as described in 
Materials and Methods after two days and fourteen days. These aggregates were washed, 
calibrated for weight concentration, and immobilized on a 96 well microplate (see 
Materials and Methods) to test their seeding ability. Figure 2 9 A  shows the kinetic time 
course of AP deposition onto equal weights of the aggregates grown in the presence of 
100 µM calmidazolium for two days and fourteen days, compared to the kinetic time 
course of AP deposition on equal weights of standard AP amyloid fibrils grown for the 
same periods of time. These results show that after two days aggregates grown in the 
presence of 100 µM calmidazolium cannot seed deposition of AP in the microplate assay. 
After fourteen days these aggregates show some seeding ability, but it is very limited 
compared to the seeding ability of normal AP fibrils grown for fourteen days. This lack 
of seeding ability agrees qualitatively with the results of the ThT assay. It is also 
consistent with the hypothesis that calmidazolium is driving AP monomer into a non-
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fibrillar aggregated state. The seeding ability of the calmidazolium aggregates after 14 
days could possibly be due to the presence of a small amount of fibrillar AP that forms 
either from AP in solution that does not interact with calmidazolium, or by a 
rearrangement of the AP that is associated with calmidazolium. The partial seeding of AP 
elongation by 14-day AP/calmidazolium aggregates fits with the fibrillar and globular 
structures observed by EM in the 14 day calmidazolium aggregates (Figure 26). 
Figure 29B shows the kinetic time course of AP deposition onto the aggregates 
grown in the presence of 10 µM calmidazolium for two days and fourteen days compared 
to the kinetic time course of AP deposition onto normal fibrils grown for the same 
periods of time. These results show that aggregates grown in the presence of 10 µM 
calmidazolium for two days also cannot seed AP deposition in the microplate assay. After 
fourteen days, however, these aggregates do show some seeding ability, although it is not 
nearly as great as that of normal fibrils grown for the same amount of time. 
We also set out to test the hypothesis that calmidazolium stimulates deposition of 
elongation competent aggregates in the microplate assay ( see above) by incubating 
gelatin blocked microplate wells at 37°C for 1 hour with either both 10 nM AP (non­
biotinylated) and I 00 µM calmidazolium chloride, only 10 nM A� (non-biotinylated), or 
only 100 µM calmidazolium chloride, then washing the wells with buffer, and conducting 
the microplate assay as described in Materials and Methods (Figure 30). The results of 
this test showed no AP extension after incubating the microplate wells with any 
combination of AP and calmidazolium, which suggests that calmidazolium is simply 
stimulating deposition of biotinyl-AP in the microplate wells, and the method of signal 
31 
generation in the assay (see Materials and Methods) creates a signal for the deposited 
biotinyl-AP, regardless of whether or not it is fibrillar. 
In addition to testing the seeding ability of these AP/calmidazolium aggregates, 
we also checked the level of protection from hydrogen/deuterium exchange of the 
aggregates. It has been shown that, in AP(l -40) fibrils, about 50% of the 39 backbone 
amide protons of AP are strongly protected from deuterium exchange, indicating that 
about 19 of the protons are involved in stable P-sheet structure. [Kheterpal, 2000 #12, 
Kheterpal, 2003 # 13] . Figure 31 A shows that AP aggregates grown in the presence of 
100 µM calmidazolium even after 14 days undergo hydrogen exchange much more 
readily than do AP fibrils. This result suggests that the amide groups of the AP peptides 
in these AP/calmidazolium aggregates are much more exposed to solvent than those of 
fibrils, and that the network of hydrogen bonds is not as great as in fibrils. This might be 
attributed to there being less P-sheet secondary structure present in these aggregates 
compared to AP fibrils (see Background). The amount of protection seen for these 
calmidazolium aggregates is essentially identical to that seen for AP protofibrils isolated 
from the normal in vitro assembly reaction (I. Kheterpal and H. Lashuel, unpublished). 
As shown in Figure 31 B AP/10 µM calmidazolium aggregates also exchange to the same 
degree as the AP/100 µM calmidazolium aggregates and protofibrils up to four days, but 
after fourteen days, they more closely resemble AP fibrils in terms of the amount of 
exposure to solvent. Could calmidazolium be stimulating the formation of a protofibrillar 
intermediate which is less strongly blocked from rearranging into fibrils at lower 
calmidazolium concentrations? If so, it could prove to be a valuable research tool in 
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Inhibition of the aggregation of amyloidogenic peptides is an attractive target for 
potential drugs to treat the diseases associated with those peptides [Lansbury, 1997 #22]. 
High throughput assays have been developed to screen a very large number of 
compounds for potential inhibitors of these amyloidogenic systems ([Berthelier, 2001 
#24], [Esler, 1997 #8]). However, these assays can also identify compounds that 
stimulate the aggregation of amyloid, as is the case with this work. Such stimulatory 
compounds have a number of potential uses. First, these compounds are of interest to 
researchers because studying their interaction with the amyloidogenic species can 
possibly offer insight into the mechanism by which amyloid is formed, as well as the 
chemical structures that are important to amyloid formation. Second, these compounds 
could be used to test the amyloid hypothesis. Do mouse models treated with these 
compounds develop Alzheimer's Disease pathology and/or cognitive defects more 
rapidly than normal? Alternatively, if the compounds stimulate deposition of a non-toxic 
form of A�, do they slow disease progress in the mouse model? If so, they could 
potentially be useful as therapeutics. 
The compounds identified in this study that stimulate A� aggregation in vitro can 
be divided into four classes based on their chemical structures (Figure 4). The first class 
is comprised of compounds containing cyclical structures of carbon and nitrogen. These 
compounds are amiloride HCl, phenamil methane sulfonate, and naftopidil 
dihydrochloride. Interestingly, amiloride and phenamil are structural analogs. Phenamil 
has the basic chemical structure of amiloride with a benzene ring attached at one of the 
nitrogen atoms. Also, based on the ECso values, phenamil is approximately as potent as 
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amiloride (ECso � 38 .5µM and 35 .5 µM respectively). Another interesting aspect of these 
two compounds is the fact that portions of their structures resemble a peptide bond ( an a­
carbon atom between C-N and ·c=0 atoms). Unfortunately, the stimulating effect of these 
compounds is not reproducible when they are freshly dissolved in DMSO (see Figures 
5A and 5B). This could be due to the fact that the compounds in the LOP AC library were 
stored in DMSO at 4°C for several months prior to the primary screen. It is possible that 
degradation products of these two compounds were responsible for the stimulation of 
aggregation observed in the primary screen. This possibility was not explored in this 
work. 
The second class of stimulators contains L-a-methyl DOPA. The catechol 
containing structure is similar to those of other compounds that have been identified as 
modulators of aggregation of the amyloid a-synuclein [Conway, 2001 #28] and inhibitors 
of polyglutamine aggregation (V. Berthelier, unpublished). In this previous work it was 
shown that the oxidized quinone forms of the catechol containing compounds are the 
active species [Conway, 200 1 #28] . It may be possible that a similar oxidized form of L­
a-methyl DOPA is responsible for the results in the primary screen of the LOP AC 
library. However, it is worth noting that the LOPAC library contained 12  catechol-like 
structures very similar to L-a-methyl DOPA, none of which had any effect on AP 
deposition in the microplate assay in our primary screen. Therefore, L-a-methyl DOPA 
may indeed be interacting with AP in the microplate assay, but due to the fact that it is 
not a very potent stimulator (ECso � 34.2 µM) and the possibility that an oxidized form of 
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the compound is indeed the active stimulating species, the uses of L-a-methyl DOPA in 
further studies of AJ3 aggregation would be very limited. 
The third class of stimulators contains NPC 15437 and 5-(nonyloxy)-tryptamine 
hydrogen oxalate. These compounds both have amphipathic characteristics. They each 
contain long hydrophobic carbohydrate chains and primary amino groups that are 
presumably protonated at pH 7 (see Figures 4A and 4B). They are also both very potent 
(EC5o 2::: 27.2 µM and 30.3 µM respectively). The amphipathic molecule hexadecyl-N­
methylpiperidinium (HMP) has been found to inhibit in vitro fibril formation [Wood, 
1996 #29]; this work was conducted in a pH 6 aggregation system, however, and is 
therefore difficult to compare to results described here. It is unclear whether the 
amphipathic characteristics of NPC 1543 7 and 5-(nonyloxy)-tryptamine hydrogen oxalate 
are primarily responsible for their stimulatory effects on AP deposition. As compounds 
likely to form micelles, it is possible that such micelles are the actual species responsible 
for stimulating AP aggregation in vitro. However, light scattering experiments to 
determine a critical micelle concentration (CMC) for NPC 15437 proved unsuccessful 
(data not shown). NPC 15437 seems to stimulate the nucleation phase of AJ3 aggregation 
(see Figure 13A), but it is unclear from the present data what the exact mechanism of 
stimulation by NPC 1543 7 might be. One possibility is that NPC 1543 7 alters the 
stabilities of key intermediates in the fibril assembly pathway, thereby altering the steady 
state concentrations of intermediates, which in tum would affect the observed rate of 
aggregation. 
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The final class of compound contains calmidazolium chloride. Calmidazolium is 
highly hydrophobic, with four phenyl groups attached to a central imidazole ring (see 
Figure 4C). Calmidazolium is also the most potent of the seven stimulators presented 
here (ECso = 21.4). Interestingly, when the LOP AC library was screened for inhibitors of 
polyglutamine (polyQ) aggregation, calmidazolium had no effect on the rate of 
aggregation up to a concentration of 100 µM (V. Berthelier, T. Richey, unpublished). 
This result suggests that there is an intrinsic mechanistic and/or structural difference 
between polyQ and AP amyloid aggregation, despite the many similarities also seen for 
these aggregates. 
It is noteworthy that even though some compounds in the LOP AC library have 
been found to inhibit polyglutamine aggregation in the microplate assay (V. Berthelier, T. 
Richey, unpublished), none of them showed any inhibitory effect on AP aggregation in 
the same assay. Even more interesting is the fact that there were quite a few compounds 
in the LOPAC library that actually stimulated AP aggregation in the microplate assay, 
and none in the polyglutamine screen, again suggesting that the mechanisms of assembly 
and/or structural stabilization of different amyloid proteins, or the roles of various amino 
acid residues of the peptide in their assembly, are quite different from one another. 
At least two different mechanisms of stimulation of AP aggregation have been 
characterized here, both of which are apparently due to interactions with non-amyloid 
states of AP (monomer and/or protofibrils). This result is exciting, as it could provide 
valuable insight into the basic mechanism of AP assembly. Also exciting is the fact that 
based on RP-HPLC and light scattering data, AP in the presence of calmidazolium forms 
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aggregates after only one day while EM images and ThT fluorescence measurements 
show that these aggregates do not appear to be fibrillar in nature. Is calmidazolium 
driving AP into a non-toxic, non-amyloidogenic conformation? If so, are there any other 
compounds that have the same properties as calmidazolium chloride (i.e., the ability to 
stimulate formation of a non-fibrillar AP aggregate)? It may be likely that there are other 
compounds similar to calmidazolium, since this work only looked at approximately 600 
out of millions of chemical compounds. If there are compounds with properties similar to 
calmidazolium, then there may be potential therapeutic applications of them. However, 
much work must be done to determine if this is a viable option or not. For instance, if 
calmidazolium truly is a potential therapeutic then it must be determined if it can act at 
physiologically relevant concentrations of AP. The microplate assay is conducted at I 0 
nM AP, while the concentration of AP in blood and cerebrospinal fluid is in the low pM 
range [Harper, 1997 #10]. It is also necessary to determine whether calmidazolium is 
stimulating the formation of a toxic aggregated state of Ap. 
Additionally, the results from the microplate assay indicate that calmidazolium in 
the presence of AP at a concentration of 10 nM stimulates aggregation instantaneously, 
but in the ThT assay at AP concentrations of 30 µM there is a delay before fibrils can be 
seen. The most likely explanation for this result is that the microplate assay detects all AP 
deposited (see Materials and Methods), regardless of whether or not it is fibrillar. The 
signal in the ThT assay only appears once fibrils are present. Also, as shown in Figure 
22B, AP in the presence of I 00 µM calmidazolium in the solution phase assay is depleted 
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after only a few hours, which is consistent with the instantaneous effect seen in the 
mi crop late assay. 
Calmidazolium chloride could prove to be a valuable tool in testing the amyloid 
hypothesis in a mouse model of AD. For instance, if protofibrils are the toxic species in 
the amyloid pathway and calmidazolium is stimulating their formation, would mouse 
models treated with calmidazolium be more prone to the neurodegenerative effects of 
AD, or would calmidazolium keep the protofibrils clustered in a large aggregated state 
that is non-toxic to cells? Also, if the toxic species is an intermediate in the amyloid 
assembly pathway, and calmidazolium is actually stimulating fibril formation as it 
originally appeared in the microplate assay, then it may actually prevent the accumulation 
of these intermediates. Of course, there is still the possibility that mouse models that are 
treated with calmidazolium will develop AD more rapidly than normal. The results of 
these mouse model experiments will undoubtedly give additional insight into the action 
of calmidazolium, and they will be important in developing potential therapeutics, but 
will likely not be immediately interpretable. In any case, calmidazolium could eventually 
give useful information about the role that AP plays in AD. 
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Figure 1 Kinetic time course of A� deposition in microplate assay ( conducted as 
described in Materials and Methods). The "fast phase" of elongation occurs over the first 
60 minutes, followed by the "slow phase". 
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Figure 2 Effect of DMSO on A� microplate extension assay (as described in Materials 
and Methods) at 30 minute time point. Results shown are average of three replicates. 
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Figure 3 Results of primary screen of LOPAC library. Results shown are average of 
triplicate measurements for each compound after 30 minutes. Stimulatory compounds 
exhibit negative inhibition. Vertical lines represent three standard deviations. 
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(A) (B) (C) 
(D) (E) 
Figure 4 Compounds exhibiting stimulation of A� aggregation in initial screen of 
LOPAC library (see Materials and Methods). A - Amiloride HCI. Initial stimulation 
observed = 96%; EC5o � 38 .5 µM. B - Phenamil methane sulfonate. Initial stimulation 
observed = 242%; EC50 2:: 35 .5  µM. C - Calmidazolium chloride. Initial stimulation 
observed = 598 %; ECso = 21 .4 µM. D - Naftopidil dihydrochloride. Initial stimulation 
observed = 150 %; ECso � 36.2 µM. E - L-a-methyl DOPA. Initial stimulation observed 
= 127%; EC5o � 34 .2 µM. 
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(F) (G) 
Figure 4 (cont.) F - 5-(nonyloxy)-tryptamine hydrogen oxalate. Initial stimulation 
observed = 1 36%; EC50 � 30.3 µM. G - NPC1 5437. Initial Stimulation observed = 
149%; EC so � 27 .2 µM. 
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Figure 5 Dose response studies ( conducted as described in Materials and Methods). EC50 
values represented on each curve by ( o ). A - Results for amiloride HCL Data points 
within the -log[ Amiloride] range of 4 - 5 were used for the linear fit. B - Results for 
phenamil methane sulfonate. Data points within the -log[Phenamil] range of 4 - 5 were 
used for the linear fit. C - Results for calmidazolium chloride. D - Results for naftopidil 
dihydrochloride. Data points within the -log[Naftopidil] range of 4.3 - 6 were used for 
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Figure 5 (cont.) E - Results for L-a-methyl DOPA. Data points within the -log[L-a­
methyl DOPA] range of 4 - 5 were used for the linear fit. F - Results for 5-(nonyloxy)­
tryptamine hydrogen oxalate. Data points within the -log[5-NHTO] range of 4 - 5 were 
used for the linear fit. G - Results for NPC 1 5437. Data points within the -
log[NPC1 5437] range of 4.3 - 6.3 were used for the linear fit. 
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Figure 6 Effect of stimulatory compounds on AP deposition in microplate assay 
( conducted as described in Materials and Methods). A - Kinetic time course of AP 
deposition in presence ( ■) and absence (A )  of 100 µM calmidazolium. B - Kinetic time 
course of AP deposition in presence (■) and absence ( A )  of 100 µM NPC 15437. C -
Kinetic time course of AP deposition in microplate assay in presence (■ ) and absence 
( A) of 100 µM amiloride HCI. D - Kinetic time course of AP deposition in microplate 
assay in presence (■ ) and absence ( A ) of 100 µM phenamil methane sulfonate. The 
kinetic time courses shown in the absence of compound were obtained on one microplate 
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Figure 7 Washout assay results for NPC 1 5437. The washout assay was conducted as 
described in Materials and Methods. A - Kinetic time course of AP deposition in 
microplate wells incubated with 1 00 µM NPC 1 5437 for 60 minutes followed by 
incubation in buff er for 2 hours prior to the assay ( ♦ ), in wells incubated with 1 00 µM 
NPC 1 5437 for 60 minutes immediately prior to the assay (1■), and wells with no NPC 
1 5437 present ( • ). B - Kinetic time course of AP deposition in microplate wells with 
1 00 µM NPC 1 5437 and fibrils present (■), wells with 1 00 µM NPC 1 5437 and no fibrils 














0 1 00 200 300 
Time (min) 
Figure 8 Washout assay results for calmidazolium chloride ( conducted as described in 
Materials and Methods). Kinetic time courses shown represent AP deposition in wells 
incubated with 100 µM calmidazolium for 60 minutes followed by a 2 hour incubation in 
buffer prior to the assay ( ♦), wells incubated with 100 µM calmidazolium for 60 minutes 
immediately prior to the assay ( ■), and wells with no calmidazolium present during the 
assay (A). The kinetic time courses shown here were obtained on the same day, and from 
the same microplate. The time course shown here in the absence of calmidazolium was 
obtained separately from that shown in Figure 5A. 
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Figure 9 Lack of requirement of fibril seeds for the stimulatory effect of calmidazolium 
chloride. The microplate assay was conducted as described in Materials and Methods 
using fibrils coated wells in the presence and absence of 100 µM calmidazolium, and 
wells without fibrils (blocked with 0.3% gelatin) in the presence and absence of 
calmidazolium. Data points shown represent the kinetic time course of AP deposition 
with 100 µM calmidazolium and fibrils present ( ♦ ), 100 µM calmidazolium with no 
fibrils present ( ■ ), and fibrils with no calmidazolium present ( _. ). 
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Figure 10 Lack of influence of blocking agent on calmidazolium chloride stimulatory 
effect. A - Kinetic time course of AP deposition on microplates blocked with 0.3% 
gelatin. B - Kinetic time course of AP deposition on microplates blocked with 0.5% 
BSA. No fibrils were present in any of the microplate wells. The washout assay was 
conducted for each microplate as described in Materials and Methods. Results are shown 
for wells incubated with 100 µM calmidazolium for 60 minutes followed by a 2 hour 
incubation in buffer prior to the assay ( ♦ ), wells incubated with 100 µM calmidazolium 
for 60 minutes immediately prior to assay (•), and 100 µM calmidazolium continuously 
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Figure 1 1  Effect of calmidazolium chloride on ThT fluorescence in presence (■) and 
absence ( ♦) of AP fibrils. ThT fluorescence values in absence of calmidazolium are 6.2 ± 
0 .4 for ThT alone and 7 1.7 ± 1.4 for ThT in the presence of fibrils. 
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Figure 12 Effect of NPC 15437 on ThT fluorescence in presence (■) and absence (♦) of 
AP fibrils. ThT fluorescence values in absence ofNPC 15437 are 6 .2 ± 0.4 for ThT alone 
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Figure 13 Effect ofNPC 15437 on AP aggregation. A - As measured by ThT 
fluorescence (see Materials and Methods). B - As measured by RP-HPLC (see Materials 
and Methods).30 µM AP in IX  PBS present in each aggregation reaction. Unseeded (-+-) 
and seeded (_._) control AP aggregation reactions (no NPC 15437 present) shown in A 
and B. A - Data points represent unseeded AP aggregation reactions in the presence of 
100 µM NPC 15437 (*), 50  µM NPC 15437 (■), 10 µM NPC 15437 (X), and 1 µM NPC 
15437 (•). B - Data points represent unseeded AP aggregation reactions in the presence 
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Figure 1 9  Effect of calmidazolium chloride on unseeded A� aggregation as measured by 
ThT fluorescence (see Materials and Methods). 30 µM A� in IX  PBS present in each 
aggregation reaction. Data points shown represent reactions with no calmidazolium 
present (--+-), 100 µM calmidazolium present (•), 30 µM calmidazolium present (*), 20 
µM calmidazolium present (+), 10 µM calmidazolium present ( • ), and 1 µM 
calmidazolium present ( ■ ). 
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Figure 20 Effect of calmidazolium chloride on AP aggregation as measured by RP­
HPLC (see Materials and Methods). 30 µM AP in lX PBS present in each aggregation 
reaction. Data points shown represent unseeded (--+-) and seeded ( ..._) controls with no 
calmidazolium present, and unseeded reactions with 1 00 µM calmidazolium (•) and 1 
µM calmidazolium (■) present. 
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Figure 21 Effect of calmidazolium chloride on unseeded AP aggregation as measured by 
90° light scattering at 450 nm (see Materials and Methods). 30 µM AP in lX  PBS present 
in each aggregation reaction. Data points represent AP aggregation in the absence of 
calmidazolium ( ♦ ), in the presence of 1 00 µM calmidazolium ( • ), in the presence of 20 
µM calmidazolium ( • ), in the presence of 1 0  µM calmidazolium ( ■ ), and in the presence 
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F igure 22 Effect of calmidazolium chloride on early stages of AJ3 aggregation. A - AP 
aggregation as monitored by light scattering at 450 nm ( conducted as described in 
Materials and Methods). B - As monitored by RP-HPLC ( conducted as described in 
Materials and Methods). Data points shown represent unseeded ( • )  and seeded ( ♦) AJ3 
aggregation reactions, and unseeded AJ3 aggregation in the presence of 1 00 µM 





































Figure 27 Afl aggregates grown in presence of 10 µM calmidazolium after 14 days. 
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Figure 29 Seeding ability of AP aggregates grown in the presence of calmidazolium 
chloride. Aggregates were collected as described in Materials and Methods. A - Kinetic 
time course of AP deposition in microplate wells coated with AP aggregates grown in the 
presence of 100 µM calmidazolium. B - Kinetic time course of AP deposition in 
microplate wells coated with AP aggregates grown in the presence of 10 µM 
calmidazolium. The microplate assay was conducted as described in Materials and 
Methods. Data points shown represent aggregates grown in the presence of 
calmidazolium for 2 days ( • )  and 14 days ( ■ ). Results are also shown for mi crop late 
wells coated with control fibrils grown in the absence of calmidazolium for 2 days (• ) 
and 14 days ( ♦ ). Microplate wells coated with AP aggregates grown for only two days in 
both the presence ( • )  and absence ( • )  of calmidazolium showed no ability to seed AP 
deposition in the microplate assay, and both sets of data are buried in the baseline of the 
figure. Results shown for microplate wells coated with control fibrils grown in the 













Figure 30 Seeding ability of Af3/calmidazolium aggregates deposited in the microplate 
assay. Prior to conducting the microplate assay ( as described in Materials and Methods), 
gelatin blocked mi crop late wells were incubated at 3 7°C for 1 hour with either 10 nM AJ3 
(non-biotinylated) plus 100 µM calmidazolium chloride ( ♦ ), only 10 nM AJ3 (non­
biotinylated) (■), or only 100 µM calmidazolium chloride ( •) washed with buffer, and 
conducting the microplate assay as described in Materials and Methods. The standard 
microplate assay was also conducted in wells coated with 100 ng of fibrils ( • )  (as 
described in Materials and Methods). No appreciable deposition of biotinyl-AJ3 can be 
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Figure 31 Deuterium content vs. time for deuterated AP aggregates. Data points 
represent the extent of deuteration of AP aggregates grown in the presence of 100 µM 
calmidazolium (A) and 10 µM calmidazolium (B) for 2 days, 4 days, and 14 days. The 
same set of control data points is shown on each graph, representing AP fibrils grown 
using the same AP stock solution as the calmidazolium aggregates (AP 1-40 normal( d= 14 
control)) and hydrogen/deuterium exchange data obtained previously for wildtype 
AP(l -40) fibrils (AP l -40 normal (8/24/01, d=12)). All aggregates were collected and 
washed as described in Materials and Methods. Deuteration of AP aggregates grown in 
the presence of calmidazolium after 4 days is about as great as that of AP protofibrils 
collected after 2 days (� 20 deuteriums) (I. Kheterpal and H. Lashuel, unpublished). After 
14 days, 10 µM calmidazolium AP aggregates show the same amount of deuteration as 
AP fibrils (� 10 deuteriums) while 100 µM calmidazolium AP aggregates remain open to 
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